Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis
Paul Hernandez1, Yohan Bossé2, Pam Bush3
1Division of Respirology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Chest
|January 29, 2025
Summary
Alpha-1-antitrypsin (A1AT) deficiency testing is recommended for individuals with COPD, asthma, or bronchiectasis. Early diagnosis and A1AT augmentation therapy can benefit patients with severe deficiency and lung disease.
Area of Science:
- Pulmonology
- Medical Genetics
Background:
- Alpha-1-antitrypsin (A1AT) deficiency is an inherited condition increasing the risk of chronic obstructive pulmonary disease (COPD).
- Many patients with severe A1AT deficiency remain undiagnosed or are diagnosed late, missing opportunities for timely intervention.
- Recent advancements in genetic testing and A1AT augmentation therapy necessitate updated clinical guidelines.
Purpose of the Study:
- To provide updated clinical practice guidelines for the diagnosis and management of A1AT deficiency.
- To incorporate new evidence from systematic reviews and meta-analyses into actionable recommendations.
- To improve early detection and treatment of A1AT deficiency-related lung diseases.
Main Methods:
- Systematic review and meta-analysis of relevant studies.
- Expert clinical input to inform recommendations.
- Development of conditional and suggestive recommendations based on synthesized evidence.
Main Results:
- Conditional recommendation for A1AT deficiency testing in individuals diagnosed with COPD, persistent adult-onset asthma with obstruction, or unexplained bronchiectasis.
- Suggested genetic testing (SERPINA1 sequencing) for high suspicion, and serum A1AT level measurement for moderate suspicion, with genetic confirmation if levels are low.
- Conditional recommendation for A1AT augmentation therapy in non-smoking or ex-smoking COPD patients with emphysema, confirmed deficiency genotypes, and severely reduced A1AT levels.
Conclusions:
- Updated guidelines emphasize broader A1AT deficiency screening in at-risk individuals.
- Genetic testing and serum A1AT levels are key diagnostic tools.
- A1AT augmentation therapy is recommended for specific COPD patients with documented deficiency and lung damage.
Related Concept Videos
01:24Cystic Fibrosis: Management
139
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
139
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
167
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
167
01:26Pulmonary Tuberculosis IV
132
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
132
01:28Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
01:30Pneumonia III: Complications and Assessment
151
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
151
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K